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Abstract
Tendinopathy is a big burden in clinics and it represents 45% of musculoskeletal lesions.
Despite the relevant social impact, both pathogenesis and development of the tendinopathy
are still under-investigated, thus limiting the therapeutic advancement in this field. The pur-
pose of this study was to evaluate the dose-dependent and time-related tissue-level
changes occurring in a collagenase-induced tendinopathy in rat Achilles tendons, in order
to establish a standardized model for future pre-clinical studies. With this purpose, 40 Spra-
gue Dawley rats were randomly divided into two groups, treated by injecting collagenase
type I within the Achilles tendon at 1 mg/mL (low dose) or 3 mg/mL (high dose). Tendon
explants were histologically evaluated at 3, 7, 15, 30 and 45 days. Our results revealed that
both the collagenase doses induced a disorganization of collagen fibers and increased the
number of rounded resident cells. In particular, the high dose treatment determined a
greater neovascularization and fatty degeneration with respect to the lower dose. These
changes were found to be time-dependent and to resemble the features of human tendino-
pathy. Indeed, in our series, the acute phase occurred from day 3 to day 15, and then pro-
gressed towards the proliferative phase from day 30 to day 45 displaying a degenerative
appearance associated with a very precocious and mild remodeling process. The model
represents a good balance between similarity with histological features of human tendino-
pathy and feasibility, in terms of tendon size to create lesions and costs when compared to
other animal models. Moreover, this model could contribute to improve the knowledge in
this field, and it could be useful to properly design further pre-clinical studies to test innova-
tive treatments for tendinopathy.
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Introduction
Tendinopathy is a big burden in clinics and it represents 45% of musculoskeletal lesions [1]. In
particular, athletes and middle-aged people are frequently affected by tendinopathy of Achilles,
patellar and supraspinatus tendons. The severity of tendon injuries ranges from transient pain
and inflammation to chronic conditions leading to tears or total tendon ruptures [1, 2]. The
poor healing capability of damaged tendons is related to their scarce blood supply and the com-
promised metabolic activity of resident cells [3] that determine an impaired tissue homeostasis
[4]. The histopathological appearance of injured tendons shows collagen degeneration and
fiber disorganization, increased vascularization and increased presence of resident cells, tissue
metaplasia, and occasionally formation of fatty and bony deposits [5, 6]. However, despite its
clinical significance, the pathogenesis and development of the tendinopathy are still under-
investigated, thus limiting the therapeutic progress in this field. In fact, the current conservative
treatments are still mainly symptomatic, whereas surgical approaches have a poor success rate
and require a long recovery time [7].
In this contest, a better knowledge of tendinopathy progression throughout its phases could
be reached through the development of an efficient in vivomodel focused on the choice of the
most effective dose of collagenase at an exact temporal window to induce the acute phase of the
disease.
Despite an ideal animal model able to reproduce all aspects of human tendinopathy has not
been identified so far, rat represents the most popular species to model the Achilles tendinopa-
thy, thanks to its suitable size for surgical approaches and tissue retrieval, and its easy handling.
Moreover, the rat model of Achilles tendinopathy has been extensively used in preclinical
research, because of the similar conditions [8, 9] and the genetic homology to humans [10].
The most common techniques to develop rodent models of tendinopathy are based on
mechanical overuse or chemical factors, such as collagenase, corticosteroids, cytokines (TGF-
β1) and substance P [8, 9]. However, the mechanical overuse model is not completely accepted
due to its scarce reproducibility and to the role of inflammation that does not equate to tendi-
nopathy [8, 11]. Among the chemical-induced tendinopathy models, it has been shown that
collagenase type I can provoke collagen fiber disruption and changes in biochemical and bio-
mechanical features of the tendon, better resembling the main histopathological characteristics
and functional impairments of human tendinopathy [8, 12, 13]. Thus, this injection model can
represent a valid approach to induce and study the development of this pathology [14]. How-
ever, despite collagenase seems to be the most interesting agent to generate a consistent and
reproducible model of tendinopathy, to date, standardized protocols have not been defined yet.
Indeed, there is no agreement on which is the concentration, volume and site of injection, and
time of occurrence of collagenase-induced lesions [13, 15–20].
The purpose of this study was to evaluate the cellular and tissue-level changes occurring in a
collagenase-induced Achilles tendinopathy in rats at different time points by using two collage-
nase concentrations. In particular, we want to accurately investigate the development of the
disease throughout its phases, in order to establish a standardized model for future pre-clinical
studies that resembles as closely as possible the human pathology.
Materials and Methods
Ethics Statement
The Mario Negri Institute for Pharmacological Research (IRFMN) Animal Care and Use Com-
mittee (IACUC) approved the study (Permit N. 06/2014-PR). The IRFMN adheres to the prin-
ciples set out in the following laws, regulations, and policies governing the care and use of
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laboratory animals: Italian Governing Law (D.lgs 26/2014; Authorization n.19/2008-A issued
March 6, 2008 by Ministry of Health); Mario Negri Institutional Regulations and Policies pro-
viding internal authorization for persons conducting animal experiments (Quality Manage-
ment System Certificate–UNI EN ISO 9001:2008 –Reg. N° 6121); the NIH Guide for the Care
and Use of Laboratory Animals (2011 edition) and EU directives and guidelines (EEC Council
Directive 2010/63/UE). The Statement of Compliance (Assurance) with the Public Health Ser-
vice (PHS) Policy on Human Care and Use of Laboratory Animals has been recently reviewed
(9/9/2014) and will expire on September 30, 2019 (Animal Welfare Assurance #A5023-01).
The animals were regularly checked by a certified veterinarian responsible for health monitor-
ing, animal welfare supervision, experimental protocols and procedure revision. All surgeries
were performed under general anesthesia, and all efforts were made to minimize suffering.
Study design
Forty 12-weeks-old male Sprague Dawley rats (Rattus norvegicus) (Envigo, Huntingdon, UK)
(mean body weight 347 ± 9 g) were used in this study. In the absence of suitable data to per-
form the power analysis, the sample size was calculated according to the Mead’s resource equa-
tion (E = N-T, 10<E<20). Thus, considering two treated limbs per animal for a total of 16
treated tendons per time-point, the sample size was calculated as follows: E = (16–1)-(4–1) =
12. The rats were randomly divided into two treated groups that were injected within the Achil-
les tendon with collagenase type I (collagenase from Clostridium histolyticum, Worthington
Lakewood, NJ, USA, 185 IU/mg): 1) collagenase 1 mg/mL defined as low dose (LD); 2) collage-
nase 3 mg/mL defined as high dose (HD). In each group, the contralateral tendon was treated
either with phosphate buffered saline (PBS) and served as control (CTRL), or left untreated
and served the sham control (S-CTRL). For each time point, 4 tendons were injected with LD,
4 tendons with HD, 4 tendons received PBS and 4 tendons were left untreated (n = 4). Tendon
explants were analyzed at 3, 7, 15, 30 and 45 days.
In vivo procedures
The rats were anesthetized via inhalation of isoflurane (3%; Merial, Duluth, Georgia, USA) and
maintained with an intraperitoneal injection of ketamine hydrochloride (80mg/kg; Imalgene,
Merial, Milan, Italy) and medetomidine hydrochloride (1mg/kg; Domitor, Pfizer, New York
City, NY, USA). All animals also received a preoperative intramuscular single injection of cefa-
zolin (30mg/kg; Cefamezin, Teva, Petah Tikva, Israel). Using aseptic technique, after shaving
and disinfection, a longitudinal 0.5 cm skin incision was performed through a medial approach
to expose by blunt dissection the central region of the Achilles tendon. Then, all animals were
injected with LD or HD of type I collagenase dissolved in 30 μL of PBS by means of a 30G nee-
dle into the central portion of the tendon, and with PBS into the contralateral tendon as con-
trols (Fig 1). Finally, the skin was sutured by separated stitches with Prolene 4/0 (Johnson &
Johnson, New Brunswick, NJ, USA). Atipamezole (1mg/kg; Antisedan, Pfizer, New York City,
NY, USA) was administered subcutaneously to recover the animals from general anesthesia.
After 3, 7, 15, 30 and 45 days, the rats were euthanized by CO2 inhalation to harvest the Achil-
les tendons for the histological investigations.
Histological analysis
Tendon specimens were fixed in 10% formalin for 24h. Then, they were dehydrated in alcohol
scale before embedding in paraffin and cutting into 5 μm longitudinal sections. The slides were
stained with haematoxylin and eosin (H&E) to evaluate the tendon morphology of collage-
nase-treated groups compared to tendons treated with PBS (CTRL) or untreated native
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tendons (S-CTRL). Photomicrographs of the tissue were captured through an Olympus IX71
light microscope and an Olympus XC10 camera (Japan). Four sections of each sample were
randomly selected and evaluated by two blinded observers to assess the tendon morphology
according to a modified semi-quantitative grading score from 0 to 3 proposed by others [21,
22] (see S1 Table). The score analyzed the fiber structure and arrangement, resident cell density
and appearance, infiltration of inflammatory cells, neovascularization and fatty deposits.
According to this grading system, a perfectly normal tendon obtained score 0, whereas a score
of 18 was assigned to maximally abnormal tendons.
Statistical analysis
Comparisons between groups and time points were analyzed by the Mann-Whitney U test
(GraphPad Prism v5.00 Software, La Jolla, CA, USA). All data are expressed as means ± standard
deviation (SD). Values of p<0.05 were considered statistically significant. The interrater reliabil-
ity of the examiners’ scores for each technique was calculated with intraclass correlation coeffi-
cient (ICC): ICC = 1, perfect reliability; ICC> 0.75, excellent reliability [23].
Results
Histopathological findings
The S-CTRL tendons showed a uniform appearance of compact, well-aligned collagen fibers
with a normal presence of spindle-shaped tenocytes disposed parallel to the fiber pattern, and,
as expected, no degenerative events were observed during the whole study period (Fig 2).
Differently, at day 3, the CTRL group exhibited a loss of fiber organization that also
appeared partially fragmented along the route of the needle injection (Fig 3A). However, a
complete recovery of the tendon structure was spontaneously achieved starting from day 7 (Fig
3D) and maintained until the last time point (day 45; Fig 3A).
Fig 1. Surgical approach. A) Longitudinal incision of the skin in the medial portion of the hind limb. B) Achilles tendon exposure
by blunt dissection. C) Injection of collagenase type I within the Achilles tendon structure.
doi:10.1371/journal.pone.0161590.g001
Fig 2. Histologic appearance of S-CTRL tendons at different time points. Representative micrographs of the
histopathological analysis; H&E staining. Scale bars 200 μm (10X).
doi:10.1371/journal.pone.0161590.g002
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The LD-treated tendons showed a mild degeneration throughout the time points. At day 3,
the LD-treated tendons showed an abnormal presence of fatty deposits associated with the loss
of fiber organization (Fig 3B, black arrows) disseminated with an increased number of slightly
rounded resident cells (Fig 3B, white arrow). At later time points, the presence of a high num-
ber of rounded cells was the most distinctive feature of degeneration in these samples, by the
way decreasing progressively until day 45 (Fig 3E, 3H, 3K and 3N).
Three days after the collagenase injection, the HD-treated tendons exhibited a moderate to
marked collagen matrix disorganization with a great increase of cell density consisting mostly
in rounded cells (Fig 3C). Moreover, a marked neoangiogenesis associated with the presence of
several inflammatory cells was found (Fig 3C, white arrow). At days 7 and 15, the HD-treated
tendons showed a complete fiber disorganization, in which the pattern was no more identifi-
able and the increased resident cells showed a rounded morphology (Fig 3F and 3I). Particu-
larly on day 7, a marked increase in vascularity was detected related to the presence of several
inflammatory cells (Fig 3F, asterisk). Furthermore, at day 15, a substantial presence of lipid
vacuoles was found (Fig 3I, black arrow). Thirty days after the HD collagenase injection, the
collagen fibers appeared disseminated of rounded and proliferative cells towards a new connec-
tive tissue deposed within the disrupted collagen fibers (Fig 3L). From day 30 to day 45, the col-
lagen structure was resized and reshaped in a parallel organization, and a decreased cell
number was detected at 45 days (Fig 3O).
In general, comparing the two treated groups, the HD collagenase induced a progressive
degeneration of the tendon tissue, with a peak around day 15, while the injection of LD collage-
nase exerted its effect earlier (day 3) with no further increase of the pathological aspects during
the following time points. Moreover, the LD treatment produced a mild degeneration with
respect to the HD, particularly in terms of angiogenesis, fatty infiltration and fiber disorganiza-
tion. Indeed, even if both treatments led to a spontaneous regeneration of the tissue at day 45,
the effect of the treatment was still evident in the HD group, while the LD-treated tendons
appeared similar to the CTRL (Fig 3N and 3O).
Histopathological score analysis
The interrater reliability of the scoring analysis performed by two blinded examiners was good
(ICC 0.73). The total and specific histopathological scores are presented in the histograms in
Fig 4A.
The injection of collagenase induced deep changes in the histological appearance of the
treated tendons resulting in a significantly worse total score of the HD and LD groups com-
pared to the CTRL group at all time-points (with the exception of LD at day 15; Fig 4A). The
HD group reached the worst total score at day 15 (16.5±2.1), while the LD one reached a maxi-
mum of 9.7±0.4 at day 3. Remarkably, the total score in the HD group decrease significantly
between day 3 and 45 (p<0.05).
Both concentrations of collagenase produced a visible damage on fiber arrangement, though
significant differences were just observed at day 15 in the HD group respect to CTRL (p<0.05)
and to LD (p<0.05). Analyzing the temporal changes in terms of disorganization of collagen
fibers, we found a progressive score worsening at least up to 15 days (1.75±0.4 at day 3, 3±0.0
at day 15, p<0.05), but then a subsequent spontaneous regeneration was observed (1.17±0.3 at
day 45, p<0.05) (Fig 4B).
Fig 3. Histological appearance of CTRL, LD and HD-treated tendons at different time points.Representative micrographs of the histopathological
analysis, H&E staining. Black arrows indicate fatty deposits; White Arrows: representative zone with high cellularity; *: vessels. Scale bars 200 μm
(10X).
doi:10.1371/journal.pone.0161590.g003
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At day 3, cell density was increased by all the treatments with a significant increase between
CTRL and HD (p<0.05) or LD groups (p<0.05) (Fig 4C). The cell density of the HD group
was higher at all time-points respect to CTRL and LD treatments, with a significant increase
respect to LD at day 15 (p<0.05).
Cell morphology was also affected by the treatments. In fact, a higher number of rounded
cells was observed in the LD and HD groups with respect to CTRL at all time-points (Fig 4D).
In particular, at day 7, both LD and HD group showed a higher score with respect to CTRL
(p<0.05). Moreover, the HD group showed significant increases also at day 15 and 45 com-
pared to CTRL (p<0.05). Nevertheless, in the HD group, a progressive decrease of rounded
cells was observed at day 45 with respect to day 3, 7 and 15 (p<0.05).
The infiltration of inflammatory cells was observed in all samples at day 3. By day 7, they
almost disappeared in CTRL group, while they were persistent in LD and HD ones. In particu-
lar, in the LD group, a significant increase was observed with respect to CTRL at day 7 and day
30 (p<0.05), whereas in the HD group it was found only at day 15 (p<0.05) (Fig 4E).
The presence of new vessels was evident in all collagenase-treated tendons (Fig 4F), specifi-
cally, their number significantly increased in both LD and HD groups with respect to CTRL up
to 15 days (p<0.05). In particular, HD groups showed a greater presence of vessels compared
to LD group at day 15 (p<0.05). A similar behavior was observed in terms of fatty deposits (Fig
4G). In fact, at day 3, both doses of collagenase caused greater fatty deposits with respect to
CTRL (p<0.05). Their increase was found at day 7 in the LD group and at day 15 in the HD
group with respect to CTRL. The HD group showed higher levels of fatty deposits at all time-
points, in particular, a significant difference was observed with respect to LD at day 15
(p<0.05).
Overall, the LD-treated tendons showed a lower degenerative score with respect to the HD
group. Moreover, the pathological changes in tendons treated with LD collagenase did not sig-
nificantly vary during the experimental observation with any differences observed between
time points neither for the total score nor for the specific features.
Discussion
Tendinopathy is an umbrella term that refers to tendon injury with unknown etiology [24].
More precisely, tendinopathy has been defined as tendinitis when a non-rupture tendon injury
is associated with a very precocious inflammatory process [25]. This process brings to mechan-
ical-related chronic lesions, commonly known as tendinosis [25]. The lack of knowledge about
the physiopathology of tendinopathy leads to misleading opinions in the presence of a host
inflammatory response and development phases of this disorder. In this context, the current
failure to offer a complete clinical picture of such a multiple etiology disease [14, 26] increases
the need of a valid animal model able to mimic the histological features of tendinopathy in
humans and to establish a standardized tool suitable for future preclinical studies.
Collagenase is considered an effective method to induce the Achilles tendinopathy in pre-
clinical models, as widely described in the literature [14, 15, 17–21, 27–30]. However, the use of
different rodent strains, different protocols in terms of amount and type of collagenase admin-
istration and follow-up time points determined a poor reproducibility of the model [13].
Aiming at standardizing a rat model of collagenase-induced tendinopathy, we carefully
compared the degenerative potential of two different concentrations of collagenase type I. In
Fig 4. Histological scores. Total (A) and specific scores for fiber arrangement (B), cell density (C) and
morphology (D), presence of inflammatory cells (E), neoangiogenesis (F) and fatty deposition (G). Data are
reported as mean±SD. *p<0.05 respect CTRL; $p<0.05respect to HD; #p<0.05 respect to different time point;
n = 4.
doi:10.1371/journal.pone.0161590.g004
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particular, we provided a complete time course evaluation of collagenase-induced Achilles ten-
dinopathy in rats, focusing on the tendon histopathology at different time points (3, 7, 15, 30
and 45 days), in order to define the most effective dose of collagenase at an exact temporal win-
dow able to generate histological evidences of tendon lesions.
The choice of the collagenase doses included in this work was based on our previous in vitro
studies, in which the dose inducing the collagen fiber disruption was validated in tendon
explants [31, 32].
Our results revealed that both LD- and HD-treated tendons displayed a disorganization of
the collagen fibers and increased the number of rounded resident cells, suggesting that a single
intra-tendinous injection was sufficient and effective to induce a prompt and severe
impairment of Achilles tendon integrity, above all in tendons treated with HD of collagenase
type I. Our findings were consistent with other studies performed in large animals, in which
the severity of the pathology was related to the amount of the injected collagenase [33]. The
morphological changes—especially occurring at day 15—resembled the histological appear-
ance of tendinopathy in humans. In fact, human Achilles tendinopathy exhibits disorganized
and smaller collagen fibers, loss of their parallel orientation, and an increased amount of
rounded-shaped tenocytes [6].
Overall, in this model, we demonstrated that the acute phase occurred from day 3 to day 15
and evolved towards a proliferative phase from day 15 to day 45 displaying a degenerative
appearance associated to a very precocious and mild remodeling process, according to what
observed by previous in vivo and human studies [6, 34]. Moreover, 25% of cases treated with
both LD and HD collagenase showed the presence of chondrocyte-like cells disseminated
within the damaged tendon fibers (see S1 Fig). This finding was consistent with other studies
describing both the presence of chondrocytes and the up-regulation of chondrogenic genes in
rat patellar and Achilles tendons after four weeks of collagenase injection [14, 27]. Similarly,
chondrocyte markers were also expressed in human clinical samples of patellar [35], supraspi-
natus [36] and Achilles tendons [6]. The impairment of the tendon feature in favor of a fibro-
cartilaginous one assumes a pathological significance. Indded, the progressive lack of elasticity
and tensile strength makes tendon more subjected to ruptures, even if no molecular mecha-
nisms and pathways occurring in human Achilles tendinopathy have been investigated yet
[37]. This condition was strengthened by some in vitro studies that demonstrated the capability
of tendon stem/progenitor cells to effectively transdifferentiate towards the chondrogenic line-
age [38–40].
The presence of fatty deposits was observed in tendons treated with HD collagenase, while
they were rarely found in the LD-treated ones. The fat infiltration is retrieved in case of poor
tendon repair. Moreover, fatty deposits were found in chronic tendinopathy in humans and in
large animals [35, 41].
Our findings showed increased neo-angiogenesis in collagenase treated samples, more
markedly visible in the HD-treated tendons than in the LD ones, above all at the earlier stages
of the disease. The presence of new vessels was mainly restricted to the peritenon and it was
combined with an initial increase of the cell number from day 3 to day 15, followed by a
decrease from day 15 to day 45. The neovascularization and the increased amount of cells
could be correlated to an inflammatory reaction. Our data were supported by several studies
that demonstrated an inflammatory reaction in humans and animal models, both in the early
overload response and in the established tendinopathy [42]. However, the role of inflammation
in tendon healing is still a greatly debated topic. Inflammation is highly beneficial to the tissue
repair thanks to the release of cytokines and growth factors that together promote neoangio-
genesis and the recruitment of resident and progenitor cells, and macrophages [43]. Neverthe-
less, how the inflammatory reaction can influence the progression of the pathology and how it
AModel of Tendinopathy Progression
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can possibly contribute to the healing process are still unanswered questions. So, since its role
in tendinopathy is uncertain, the presence (or absence) of an inflammatory response in our
model would not have represented a crucial parameter to be considered in comparison with
the human disease, thus, it was not deeply investigated. Despite our study was based only on
histological evaluations, it was able to resemble the most important tendinopathy features in
terms of tissue damages. These outcomes need to be examined in depth through quantitative
analyses to assess the correlation of the histological findings with biochemical analyses, such as
glycosaminoglycan, collagen and DNA contents, as well as with biomechanical parameters.
Overall, the results of this study suggested that the HD collagenase-induced tendinopathy is
a reliable model in rats, resembling the human disease. In particular, our results demonstrated
that collagenase type I efficiently induced three distinct stages of the disease over time, thus
offering the opportunity to accurately investigate the pathological progression in a well-con-
trolled establishment of this complex injury. More importantly, this model could be used to
test novel therapies during the three-stage tendon disorder to achieve the most effective results
in patients.
Supporting Information
S1 Fig. Chondrocyte-like cells in LD and HD treated tendon at day45. Representative micro-
graphs of the histopathological analysis; H&E staining. Scale bars 100 μm (20X).
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S1 Table. Grading system for the tendon histological evaluation.
(DOCX)
Author Contributions
Conceptualization: ABL DS LDG.
Data curation: CPOMV DS ADG.
Formal analysis:MVDS ADG.
Funding acquisition: SS LDG.
Investigation: CPO ABL MVMB.
Methodology: CPO ABL MB.





Writing - original draft: CPO ABL DS.
Writing - review & editing: CPO ABL MVMB ADG LDG.
References
1. Maffulli N, Wong J, Almekinders L. Types and epidemiology of tendinopathy. Clin Sports Med 2003;
22:675–692. PMID: 14560540
A Model of Tendinopathy Progression
PLOS ONE | DOI:10.1371/journal.pone.0161590 August 22, 2016 10 / 12
2. Sharma P, Maffulli N. Biology of tendon injury: healing, modeling and remodeling. Musculoskelet Neu-
ronal Interact 2006; 6:181–190.
3. Hildebrand KA, Jia F, Woo SL. Response of donor and recipient cells after transplantation of cells to the
ligament and tendon. Microsc Res Tech 2002; 58:34–38. PMID: 12112420
4. Woo SLY, Thay TQ, Abramowitch SD, Gilbert T. Structure and function of ligaments and tendons. In:
Mow VC, HayesWC, editors. Basic orthopaedic Biomechanics & Mechanobiology. Philadelphia: Lip-
pincott, Williams &Wilkins; 2005. pp. 301–342.
5. Maffulli N, Kader D. Tendinopathy of tendon achilles. J Bone Joint Surg Br 2002; 84: 1–8.
6. Maffulli N, Reaper J, Ewen SWB, Waterston SW, Barrass V. Chondral metaplasia in calcific tendinopa-
thy of the Achilles tendon. Clin J Sport Med 2006; 16:329–334. PMID: 16858217
7. Bagnaninchi PO, Yang Y, El Haj AJ, Maffulli N. Tissue engineering for tendon repair. Br J Sports Med
2007; 41:e10. PMID: 17062654
8. Hast MW, Zuskov A, Soslowsky LJ. The role of animal models in tendon research. Bone Joint Res
2014; 3:193–202. doi: 10.1302/2046-3758.36.2000281 PMID: 24958818
9. Warden SJ. Animal models for the study of tendinopathy. Br J Sports Med 2007; 41:232–240. PMID:
17127722
10. Abbott A. Laboratory animals: the renaissance rat. Nature. 2004; 428:464–466. PMID: 15057803
11. Shepherd JH, Screen HRC. Fatigue loading of tendon. Int J Exp Pathol 2013; 94:260–270. doi: 10.
1111/iep.12037 PMID: 23837793
12. Dirks RC, Warden SJ. Models for the study of tendinopathy. J Musculoskelet Neuronal Interact 2011;
11:141–149. PMID: 21625051
13. Lake SP, Ansorge HL, Soslowsky LJ. Animal models of tendinopathy. Disabil Rehabil 2008; 30:1530–
1541. doi: 10.1080/09638280701785460 PMID: 18608372
14. Lui PPY, Maffulli N, Rolf C, Smith RKW.What are the validated animal models for tendinopathy? tendi-
nopathy animal model. Scand J Med Sci Sports 2011; 21:13–17.
15. Casalechi HL, Leal-Junior EC, Xavier M, Silva JA Jr, de Carvalho Pde T, Aimbire F, et al. Low-level
laser therapy in experimental model of collagenase-induced tendinitis in rats: effects in acute and
chronic inflammatory phases. Lasers Med Sci 2013; 28:989–995. doi: 10.1007/s10103-012-1189-x
PMID: 22926534
16. Lui PP, Chan LS, Fu SC, Chan KM. Expression of sensory neuropeptides in tendon is associated with
failed healing and activity-related tendon pain in collagenase-induced tendon injury. Am J Sports Med
2010; 38:757–764. doi: 10.1177/0363546509355402 PMID: 20139325
17. Machova Urdzikova L, Sedlacek R, Suchy T, Amemori T, Ruzicka J, Lesny P, et al. Human multipotent
mesenchymal stem cells improve healing after collagenase tendon injury in the rat. Biomed Eng Online
2014; 13:42. doi: 10.1186/1475-925X-13-42 PMID: 24712305
18. Marcos RL, Leal-Junior EC, Arnold G, Magnenet V, Rahouadj R, Wang X, et al. Low-level laser therapy
in collagenase-induced Achilles tendinitis in rats: analyses of biochemical and biomechanical aspects.
J Orthop Res 2012; 30:1945–1951. doi: 10.1002/jor.22156 PMID: 22674405
19. Tsai YP, Chang CW, Lee JS, Liang JI, Hsieh TH, Yeh ML, et al. Direct radiofrequency application
improves pain and gait in collagenase-induced acute Achilles tendon injury. Evid Based Complement
Alternat Med 2013; doi: 10.1155/2013/402692
20. Yoo SD, Choi S, Lee GJ, Chon J, Jeong YS, Park HK, et al. Effects of extracorporeal shockwave ther-
apy on nanostructural and biomechanical responses in the collagenase-induced Achilles tendinitis ani-
mal model. Lasers Med Sci 2012; 27:1195–1204. doi: 10.1007/s10103-011-1049-0 PMID: 22274874
21. Chen L, Liu JP, Tang KL, Wang Q, Wang GD, Cai XH, et al. Tendon derived stem cells promote plate-
let-rich plasma healing in collagenase-induced rat achilles tendinopathy. Cell Physiol Biochem 2014;
34:2153–2168. doi: 10.1159/000369659 PMID: 25562162
22. Kamineni S, Butterfield T, Sinai A. Percutaneous ultrasonic debridement of tendinopathy-a pilot Achil-
les rabbit model. J Orthop Surg Res 2015; 10:70. doi: 10.1186/s13018-015-0207-7 PMID: 25986341
23. Fleiss JL. Statistical Methods for Rates and Proportions. New York, NY, USA: JohnWiley & Sons;
1981.
24. Scott A, Backman L, Speed C. Tendinopathy-Update on Pathophysiology. J Orthop Sports Phys Ther
2015; 21:1–39.
25. Maffulli N, Khan KM, Puddu G. Overuse tendon conditions: time to change a confusing terminology.
Arthroscopy 1998; 14:840–843. PMID: 9848596
26. Yuan T, Zhang J, Zhao G, Zhou Y, Zhang CQ, Wang JH. Creating an Animal Model of Tendinopathy by
Inducing Chondrogenic Differentiation with Kartogenin. PLoS One 2016; 11:e0148557. doi: 10.1371/
journal.pone.0148557 PMID: 26848746
A Model of Tendinopathy Progression
PLOS ONE | DOI:10.1371/journal.pone.0161590 August 22, 2016 11 / 12
27. Lui PP, Fu SC, Chan LS, Hung LK, Chan KM. Chondrocyte phenotype and ectopic ossification in colla-
genase-induced tendon degeneration. J Histochem Cytochem 2009; 57:91–100. doi: 10.1369/jhc.
2008.952143 PMID: 18824634
28. Lui PP, Wong Y. Higher BMP/Smad sensitivity of tendon-derived stem cells (TDSCs) isolated from the
collagenase-induced tendon injury model: possible mechanism for their altered fate in vitro. BMCMus-
culoskelet Disord 2013; 14:248. doi: 10.1186/1471-2474-14-248 PMID: 23964681
29. Pires D, Xavier M, Araújo T, Silva JA Jr, Aimbire F, Albertini R. Low-level laser therapy (LLLT; 780 nm)
acts differently on mRNA expression of anti- and pro-inflammatory mediators in an experimental model
of collagenase-induced tendinitis in rat. Lasers Med Sci 2011; 26:85–94. doi: 10.1007/s10103-010-
0811-z PMID: 20737183
30. Solchaga LA, Bendele A, Shah V, Snel LB, Kestler HK, Dines JS, et al. Comparison of the effect of
intra-tendon applications of recombinant human platelet-derived growth factor-BB, platelet-rich plasma,
steroids in a rat achilles tendon collagenase model. J Orthop Res 2014; 32:145–150. doi: 10.1002/jor.
22483 PMID: 24018586
31. de Girolamo L, Stanco D, Galliera E, ViganòM, Colombini A, Setti S, et al. Low frequency pulsed elec-
tromagnetic field affects proliferation, tissue-specific gene expression, and cytokines release of human
tendon cells. Cell Biochem Biophys 2013; 66:697–708. doi: 10.1007/s12013-013-9514-y PMID:
23345006
32. de Girolamo L, Stanco D, Galliera E, ViganòM, Lovati AB, Marazzi MG, et al. Soft-focused extracorpo-
real shock waves increase the expression of tendon-specific markers and the release of anti-inflamma-
tory cytokines in an adherent culture model of primary human tendon cells. Ultrasound Med Biol 2014;
40:1204–1215. doi: 10.1016/j.ultrasmedbio.2013.12.003 PMID: 24631378
33. Williams IF, McCullagh KG, Goodship AE, Silver AI. Studies on the pathogenesis of equine tendonitis
following collagenase injury. Res Vet Sci 1984; 36: 326–338. PMID: 6087432
34. Soslowsky LJ, Carpenter JE, DeBano CM, Banerji I, Moalli MR. Development and use of an animal
model for investigations on rotator cuff disease. J Shoulder Elbow Surg 1996; 5: 383–392. PMID:
8933461
35. Rui YF, Lui PP, Rolf CG, Wong YM, Lee YW, Chan KM. Expression of chondro-osteogenic BMPs in
clinical samples of patellar tendinopathy. Knee Surg Sports Traumatol Arthrosc 2012; 20:1409–1417.
doi: 10.1007/s00167-011-1685-8 PMID: 21946950
36. Chard MD, Cawston TE, Rilely GP, GreshamGA, Hazleman BL. Rotator cuff degeneration and lateral
epicondylitis–comparative histological study. Ann Rheum Dis 1994; 53:30–34. PMID: 8311552
37. Burssens A, Forsyth R, Bongaerts W, Jagodzinski M, Mahieu N, Praet M, et al. Arguments for an
increasing differentiation towards fibrocartilaginous components in midportion Achilles tendinopathy.
Knee Surg Sports Traumatol Arthrosc 2013; 21:1459–1467. doi: 10.1007/s00167-012-2203-3 PMID:
23001016
38. Bi Y, Ehirchiou D, Kilts TM, Inkson CA, Embree MC, SonoyamaW, et al. Identification of tendon stem/
progenitor cells and the role of the extracellular matrix in their niche. Nat Med 2007; 13:1219–1227.
PMID: 17828274
39. Lovati AB, Corradetti B, Lange Consiglio A, Recordati C, Bonacina E, Bizzaro D, et al. Characterization
and differentiation of equine tendon-derived progenitor cells. J Biol Regul Homeost Agents 2011;
25:75–84.
40. Stanco D, ViganòM, Perucca Orfei C, Di Giancamillo A, Peretti GM, Lanfranchi L, et al. Multidifferentia-
tion potential of human mesenchymal stem cells from adipose tissue and hamstring tendons for muscu-
loskeletal cell-based therapy. Regen Med 2015; 10:729–743. doi: 10.2217/rme.14.92 PMID:
25565145
41. Cook JL, Purdam CR. Is tendon pathology a continuum? A pathology model to explain the clinical pre-
sentation of load-induced tendinopathy. Br J Sports Med 2009; 43:409–416. doi: 10.1136/bjsm.2008.
051193 PMID: 18812414
42. Rees JD, Stride M, Scott A. Tendons—time to revisit inflammation. Br J Sports Med 2014; 48:1553–
1557. doi: 10.1136/bjsports-2012-091957 PMID: 23476034
43. Battery L, Maffulli N. Inflammation in overuse tendon injuries. Sports Med Arthrosc 2011; 19:213–217.
doi: 10.1097/JSA.0b013e31820e6a92 PMID: 21822104
A Model of Tendinopathy Progression
PLOS ONE | DOI:10.1371/journal.pone.0161590 August 22, 2016 12 / 12
